Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Clinical trial NCT03379051 · TERMINATED
Trial details
- NCT number
- NCT03379051
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-27
- Primary completion
- 2022-05-26
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.